Market Intelligence Center  Jun 26  Comment 
MarketIntelligenceCenter.com’s patented option-trade picking algorithm found two trade ideas on Novartis AG (NVS) today after it traded between between $100.69 and $101.70 before closing at $100.82 on Thursday. For more conservative investors,...
newratings.com  Jun 26  Comment 
Novartis drug Farydak® recommended by CHMP for EU approval to treat multiple myeloma, providing patients a new mechanism of action Novartis International AG / Novartis drug Farydak® recommended by CHMP for EU approval to treat multiple...
FiercePharma  Jun 25  Comment 
Two union funds are suing Novartis, claiming that the Swiss drugmaker used "sham" patent-infringement claims to delay a generic version of its blockbuster leukemia drug Gleevec. Though just the latest in a series of legal battles over drug patent...
FiercePharma  Jun 22  Comment 
Pharma ad budgets may be set to dip overall in 2016, but the industry's big spenders will still be shelling out $2 billion each--or more--to promote their drugs, according to an annual spending study.
FiercePharma  Jun 19  Comment 
Novartis' eye drug Lucentis has long had a target on its back from biosimilar makers who would love to get some piece of the $4 billion in annual sales it racks up. Now an Indian drugmaker says it has hit that mark.
Market Intelligence Center  Jun 19  Comment 
For a hedged play on Novartis AG (NVS) MarketIntelligenceCenter.com’s algorithms selected the Oct. '15 $100.00 covered call for a net debit in the $96.56 area. That is also the break-even stock price for the covered call. This trade will return...
newratings.com  Jun 19  Comment 
BASEL (dpa-AFX) - Sandoz, a Novartis (NVS) company, announced the US launch of Glatopa, the first generic version of Teva's (TEVA) Copaxone (glatiramer acetate injection) 20 mg/ml one-time-daily multiple sclerosis therapy. "Sandoz, together...
newratings.com  Jun 18  Comment 
Sandoz announces US launch of Glatopa(TM), the first generic competitor to Copaxone® 20mg Novartis International AG / Sandoz announces US launch of Glatopa(TM), the first generic competitor to Copaxone® 20mg . Processed and transmitted by...
MedPage Today  Jun 18  Comment 
(MedPage Today) -- Rivastigmine improves gait disturbances in early study
FiercePharma  Jun 18  Comment 
Novartis has had a complicated year: Three months ago, the Swiss drugmaker closed its multipart asset swap with GlaxoSmithKline, sending most of its troubled vaccines business to GSK and taking on the U.K. drugmaker's oncology business.


Fuerralz? That's marvelously good to know.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki